Business Wire

ISC High Performance 2022: Liqid Introduces EMEA Attendees to Composable Disaggregated Infrastructure for a More Flexible, Sustainable Data Center

30.5.2022 09:30:00 EEST | Business Wire | Press release

Share

Liqid, the world’s leading software company delivering data center composability, announced today it is taking part in ISC High Performance 2022 (booth #B211), providing live demonstrations of the company’s Liqid Matrix™ composable disaggregated infrastructure (CDI) software. Dynamic infrastructure orchestration from Liqid delivers improved IT performance and agility for the most demanding next-gen applications such as artificial intelligence and machine learning (AI+ML), edge computing deployments, high-performance computing, and virtualization. Increased efficiency helps minimize the data center footprint, delivering software-defined ability to share resources no matter where they physically reside, making Liqid solutions fundamental to a more sustainable data center ecosystem. Available today for customers in the Europe, Middle East, & Africa (EMEA) region, solutions based on Liqid Matrix CDI software deliver architectural flexibility and efficiency to maximize time-to-value for high-value applications across industry verticals.

“AI applications, edge data center deployments reading multiple streams of sensor data, HPC-driven genomic research, and even more traditional software deployments like virtualization are taxing traditional data center infrastructures, increasingly making them neither practical nor sustainable,” said Paul Silver, Vice President and General Manager, EMEA, Liqid. “We’re excited to be able to bring our composable solutions to ISC High Performance attendees and the wider EMEA market to help better address the sea changes taking place in the data center ecosystems.”

Liqid Matrix software enables IT users to configure bare-metal servers in seconds. With Liqid Matrix, independent resource pools are orchestrated on-demand to instantly address the requirements of the specific workload. Once the workload is complete, resources are released back into the pool for use by other applications. This eliminates the need for costly overprovisioning of infrastructure, reduces power and cooling requirements, and enables the most efficient and sustainable data center architectures.

Liqid offers EMEA customers a cost-effective way to disaggregate and pool data center resources at large scale via software, across all industry-standard fabrics, for dynamically configurable, bare-metal servers. With composable disaggregated infrastructure solutions from Liqid, IT users can:

  • Accelerate Time-to-Value: Dynamically configure servers in seconds to meet exacting workload requirements. Create configurations that aggregate the power of dozens of GPUs and other accelerators as required.
  • Improve IT Agility: Scale resources like compute, networking, NVMe storage, GPU, FPGA, and storage-class memory beyond a server’s physical limitations, across all industry-standard fabrics, with just a couple of clicks; when data center devices are no longer needed, they are released back to the pool to be used by other applications. Leverage Liqid Command Center’s RESTful API and integrations with popular tools like Ansible to automate the provisioning of bare‐metal resources.
  • Increase Efficiency: Only purchase resources when they’re needed. Extend the life cycle of existing IT server investments. Better manage costs associated with data center footprint with greater infrastructure utilization.

“Liqid is a company that offers a flexible, software-defined infrastructure designed to optimize the access and usage of high-value IT components. Liqid has worked to create what it called ‘composable disaggregated infrastructure’ that frees IT users from vendor lock-in and traditional purchasing cycles, enabling them to build a living data center architecture that changes to meet their business needs and scales as required,” wrote senior analyst Scott Sinclair and senior research analyst Moya Keane of Enterprise Strategy Group (ESG), a division of TechTarget, in a recent ESG Showcase. “A composable infrastructure provides significant improvements to performance, architectural optimization, hardware utilization issues, and, importantly, footprint efficiency—basically eliminating the urge to overprovision.”

To download ESG’s “Why IT Must Prioritize Sustainability,” go here. Schedule an appointment with an expert on solutions based on Liqid Matrix CDI software and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.

About Liqid

Liqid’s composable infrastructure software platform, Liqid Matrix, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Robert Brumfield
Sr. Director, Global Communications
Liqid
917 224 7769
brumfield.bob@liqid.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye